Nkarta (NKTX)
(Delayed Data from NSDQ)
$6.87 USD
+0.05 (0.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
NKTX 6.87 +0.05(0.73%)
Will NKTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NKTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NKTX
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
NKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
Should You Buy Nkarta (NKTX) Ahead of Earnings?
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
Other News for NKTX
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Amgen’s Blincyto data send Cullinan higher
Commit To Purchase Nkarta At $5, Earn 31.3% Annualized Using Options
12 Health Care Stocks Moving In Friday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)